Furthermore, high-molecular-weight monoclonal antibodies are generally employed, such as Bevacizumab targeting the VEGF ligand to inhibit angiogenesis [127] and Atezolizumab targeting the PD-L1 ligand on tumor cells to enhance immune response [128]. This evidence concerns the gene VEGFA and neoplasm.